Eli Lilly is the structural winner of the incretin (GLP-1) super-cycle and is converting that lead into the deepest next-generation obesity pipeline in the industry. The tirzepatide franchise (Mounjaro diabetes + Zepbound obesity) drove FY2025 revenue to $65.2B (+45% YoY) and Q1 2026 to $19.8B (+56%), with Lilly holding ~60% of the US GLP-1 prescription market and now also leading Novo Nordisk ex-US. The thesis is no longer just 'tirzepatide is winning' — it is that Lilly owns the next three category-defining assets simultaneously: orforglipron/Foundayo (FDA-approved April 1, 2026 as the first oral small-molecule GLP-1, manufacturable at pill scale and price points that open the global mass market) and retatrutide (triple GIP/GLP-1/glucagon agonist, TRIUMPH-1 28.3-30.3% weight loss, best-in-class, FDA filing Q4 2026/Q1 2027). Management raised FY2026 guidance after Q1 to $82-85B revenue and $35.50-37.00 non-GAAP EPS. The risk is not whether obesity demand exists — it is pricing erosion (low-to-mid-teens US price headwind from MFN/Medicare access deals) and an intensifying competitive arms race (Novo amycretin/oral Wegovy, Amgen MariTide, Roche CT-388). At ~48x TTM non-GAAP / ~26x CY2027E EPS, the stock prices continued execution but not the manufacturing and pipeline moat that separates Lilly from the field.
| Scenario | Prob. | Target | Driver |
|---|---|---|---|
| Bull | 30% | $1,560.00 | Orforglipron/Foundayo launch exceeds expectations — oral pill unlocks a large naive/mass-market cohort, adding $8B+ annualized run-rate by end-2027 |
| Base | 50% | $1,200.00 | FY2026 lands within or near raised guidance ($82-85B revenue, $35.50-37.00 non-GAAP EPS); CY2027E grows ~25% off that base |
| Bear | 20% | $760.00 | Price erosion accelerates beyond low-to-mid-teens as MFN, Medicare, and TrumpRx dynamics plus oral-pill price competition compress GLP-1 net pricing |
Initial deep research: Foundayo approval + Q1 2026 print + GLP-1 competitive landscape
Positioning skews toward near-term upside